Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Takeda Pharmaceutical Co. Ltd (TAK) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript

Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript

Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million

Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda

Liver Therapy Forum weekly digest provides an overview of what's happening in Liver therapeutics in 2019. This week's focus is Takeda.

Takeda And HemoShear Therapeutics: The NASH Collaboration

Let's see if Takeda (TAK) stock is a good choice for value-oriented investors right now from multiple angles.

Is Takeda (TAK) a Profitable Stock for Value Investors Now?

Takeda Pharmaceutical Co., Ltd. (TKPHF) CEO Christophe Weber on Q1 2019 Results - Earnings Call Transcript

Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters.

Takeda kicks off sale of Western European drugs: sources

Bristol-Myers

Celgene

Telesis Bio Inc

The most prominent positions in Seth Klarman (Trades, Portfolio) equity portfolio are well-known and covered by the financial media.

Seth Klarman's Favorite Biotech Positions

Novartis

Takeda Pharmaceutical Co Ltd agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of Britain's Shire.

Takeda sells dry eye drug to Novartis to help cut debt

Shares of Takeda fell 12% in the last month for no reason.

Why The Drop In Takeda Pharmaceutical Is Overdone

Takeda Pharmaceutical Company Limited (TAK) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Takeda Pharmaceutical Enters Oversold Territory

News for Takeda Pharmaceutical Stock (TAK)